


World Journal of *Gastroenterology*

World J Gastroenterol 2017 June 21; 23(23): 4135-4316





EDITORIAL

- 4135 Attenuated adenomatous polyposis of the large bowel: Present and future
Roncucci L, Pedroni M, Mariani F
- 4140 Evolution of associating liver partition and portal vein ligation for staged hepatectomy: Simpler, safer and equally effective methods
Peng SY, Wang XA, Huang CY, Zhang YY, Li JT, Hong DF, Cai XJ

REVIEW

- 4146 Antioxidant dietary approach in treatment of fatty liver: New insights and updates
Ferramosca A, Di Giacomo M, Zara V
- 4158 *Helicobacter pylori* BabA in adaptation for gastric colonization
Ansari S, Yamaoka Y

MINIREVIEWS

- 4170 Advances in surgical management for locally recurrent rectal cancer: How far have we come?
Lee DJK, Sagar PM, Sadacharam G, Tan KY

ORIGINAL ARTICLE

Basic Study

- 4181 Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease
Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P
- 4191 Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model
Dondorf F, Fahrner R, Ardelt M, Patsenker E, Stickel F, Dahmen U, Settmacher U, Rauchfuß F
- 4200 Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an *in vivo* model
Dianzani C, Foglietta F, Ferrara B, Rosa AC, Muntoni E, Gasco P, Della Pepa C, Canaparo R, Serpe L
- 4211 Relevance of proteolysis and proteasome activation in fatty liver graft preservation: An Institut Georges Lopez-1 vs University of Wisconsin appraisal
Zaouali MA, Panisello-Roselló A, Lopez A, Castro Benítez C, Folch-Puy E, García-Gil A, Carbonell T, Adam R, Roselló-Catafau J

- 4222** Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2

Kim JE, Lee SY, Kim H, Kim KJ, Choe WH, Kim BJ

- 4233** Inhibition of N-methyl-N-nitrosourea-induced gastric tumorigenesis by Liuwei Dihuang Pill in db/db mice

Zhuang S, Jian YM, Sun YN

- 4243** miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma

Feng J, Qi B, Guo L, Chen LY, Wei XF, Liu YZ, Zhao BS

Case Control Study

- 4252** Pancreas preserving distal duodenectomy: A versatile operation for a range of infra-papillary pathologies

Mitchell WK, Thomas PF, Zaitoun AM, Brooks AJ, Lobo DN

Retrospective Study

- 4262** Clinical importance of colonoscopy in patients with gastric neoplasm undergoing endoscopic submucosal dissection

Tsuchida C, Yoshitake N, Kino H, Kaneko Y, Nakano M, Tsuchida K, Tominaga K, Sasai T, Masuyama H, Yamagishi H, Imai Y, Hiraishi H

- 4270** Outcomes of right-lobe and left-lobe living-donor liver transplantations using small-for-size grafts

She WH, Chok KSH, Fung JYY, Chan ACY, Lo CM

Clinical Trials Study

- 4278** Potential application of neogalactosylalbumin in positron emission tomography evaluation of liver function

Du SD, Li SH, Jin B, Zhu ZH, Dang YH, Xing HQ, Li F, Wang XB, Lu X, Sang XT, Yang HY, Zhong SX, Mao YL

Observational Study

- 4285** Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease

Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-Collet C

- 4293** New totally intracorporeal reconstructive approach after robotic total gastrectomy: Technical details and short-term outcomes

Parisi A, Ricci F, Gemini A, Trastulli S, Cirocchi R, Palazzini G, D'Andrea V, Desiderio J

EVIDENCE-BASED MEDICINE

- 4303** Substantial hepatic necrosis is prognostic in fulminant liver failure

Ndekwe P, Ghabril MS, Zang Y, Mann SA, Cummings OW, Lin J

CASE REPORT

- 4311** Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a *PIK3CA* mutation

Bian JL, Wang MM, Tong EJ, Sun J, Li M, Miao ZB, Li YL, Zhu BH, Xu JJ

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Akira Hokama, MD, PhD, Professor, Department of Endoscopy, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] released by Clarivate Analytics (Former Thomson Reuters) cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Fen-Fen Zhang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
 ISSN 1007-9327 (print)
 ISSN 2219-2840 (online)

LAUNCH DATE
 October 1, 1995

FREQUENCY
 Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
 Jin-Lei Wang, Director
 Yuan Qi, Vice Director
 Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501,
 Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: editorialoffice@wjgnet.com
 Help Desk: <http://www.fpublishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501,
 Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: bpoffice@wjgnet.com
 Help Desk: <http://www.fpublishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
 June 21, 2017

COPYRIGHT
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.fpublishing.com>

Attenuated adenomatous polyposis of the large bowel: Present and future

Luca Roncucci, Monica Pedroni, Francesco Mariani

Luca Roncucci, Monica Pedroni, Francesco Mariani, Department of Diagnostic and Clinical Medicine, and Public Health, University of Modena and Reggio Emilia, I-41125 Modena, Italy

Author contributions: Roncucci L, Pedroni M and Mariani F conceived the issues that formed the content of the manuscript; Roncucci L wrote the manuscript; Pedroni M and Mariani F discussed and edited the manuscript.

Conflict-of-interest statement: The authors have no conflict of interest to disclose.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Luca Roncucci, MD, PhD, Department of Diagnostic and Clinical Medicine, and Public Health, University of Modena and Reggio Emilia, Policlinico, Via Del Pozzo 71, I-41125 Modena, Italy. luca.roncucci@unimore.it
Telephone: +39-59-4224052
Fax: +39-59-4222958

Received: January 27, 2017

Peer-review started: February 6, 2017

First decision: March 16, 2017

Revised: April 3, 2017

Accepted: May 9, 2017

Article in press: May 9, 2017

Published online: June 21, 2017

Abstract

Attenuated adenomatous polyposis (AAP) is a poorly

understood syndrome, that can be defined as the presence of 10-99 synchronous adenomas in the large bowel, and it is considered a phenotypic variant of familial adenomatous polyposis (FAP). This definition has the advantage of simplicity, but it may include sporadic multiple adenomas of the large bowel at an extreme, or FAP cases on the other side. AAP shows a milder phenotype than FAP, with an older age of onset of adenomas and cancer, and less frequent extracolonic manifestations. AAP may be diagnosed as a single case in a family or, less frequently, it may be present in other family members, and it shows distinct pattern of inheritance. In less than 50% of cases, it may be caused by adenomatous polyposis coli (*APC*) or *MUTYH* mutations, referred to as *APC*-associated polyposis, inherited as an autosomal dominant trait, or *MUTYH*-associated polyposis, which shows an autosomal recessive mechanism of inheritance, respectively. Surveillance should rely on colonoscopy at regular intervals, with removal of adenomas and careful histological examination. When removal of polyps is not possible or advanced lesions are observed, the surgical approach is mandatory, being subtotal colectomy with ileo-rectal anastomosis the treatment of choice. Studies on this syndrome are lacking, and controversies are still present on many issues, thus, other clinical and genetic studies are requested.

Key words: Attenuated adenomatous polyposis; Genetic testing; Surveillance; Attenuated familial adenomatous polyposis; Adenomatous polyposis coli; *MUTYH*

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Attenuated adenomatous polyposis is a poorly understood syndrome, which may be defined as the presence of 10-99 synchronous adenomas in the large bowel, when at least 50% of the polyps removed are adenomatous. It is a variant of Familial Adenomatous Polyposis with a milder phenotype. In less than 50%

of cases, it is caused by adenomatous polyposis coli (*APC*) or *MUTYH* mutations, and less frequently by other genes. Surveillance should rely on colonoscopy at regular intervals, with removal of adenomas and careful histological examination. If removal of all polyps is not possible or advanced lesions are observed, the surgical treatment is mandatory.

Roncucci L, Pedroni M, Mariani F. Attenuated adenomatous polyposis of the large bowel: Present and future. *World J Gastroenterol* 2017; 23(23): 4135-4139 Available from: URL: <http://www.wjnet.com/1007-9327/full/v23/i23/4135.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i23.4135>

INTRODUCTION

Familial adenomatous polyposis (FAP) is a disease characterized by the presence of at least 100 adenomas of the large bowel, several extracolonic manifestations, and it is inherited as an autosomal dominant trait^[1]. It is caused by constitutional mutations in the adenomatous polyposis coli (*APC*) gene^[2,3], and, less frequently, by mutations in the *MUTYH* gene^[4]. Attenuated familial adenomatous polyposis (AFAP) is considered a phenotypic variant of FAP, whose main feature is the presence in the large bowel of less than 100 synchronous adenomas^[5]. "Attenuated" also means that the disease has a milder phenotype than the classical FAP. Indeed, patients with AFAP develop adenomas and cancer at an older age, and extracolonic manifestations are less frequent than in FAP^[5,6]. Moreover, only one individual is affected in most families^[7]. Nowadays AFAP may be included in the broad category of adenomatous polyposis syndromes^[8].

The first approach to an attenuated adenomatous polyposis (AAP) should be clinical, and it is extremely important for the further management of the disease. The first step for a correct evaluation of patients with an intestinal polyposis must be a careful collection of the family history of cancers and premalignant lesions of the gastrointestinal tract, in order to get an estimate of the risk of an inherited predisposition to cancer. Particular attention should be paid to vertical transmission of the disease (from a generation to the next), sibling aggregation, and age at diagnosis of cancers in the family, especially for first- and second-degree relatives, although very often we are dealing with single cases in a family. Another milestone in the management is the particular attention that should be put on the histology of polyps removed in the large bowel. Polyps are usually adenomas, but it is not infrequent to find other histological variants (hyperplastic, serrated, hamartomatous, juvenile, or mixed), sometimes associated with adenomas. It is conceivable to define an adenomatous polyposis when more than 50% of polyps are adenomas, otherwise other polyposis syndromes should be taken into

account^[9]. Then, relying on the familial pedigree and on the characteristics of the individual phenotype of the proband, genetic testing for a germline mutation should be proposed to the proband, or to the most informative family members, when appropriate. In the case of attenuated adenomatous polyposis, firstly *APC* and *MUTYH* mutations should be searched for^[8].

Indeed, constitutional mutations in *APC* or *MUTYH* genes were found in a large fraction of patients with AFAP^[9-11]. Accordingly, now the term *APC*-associated polyposis (AFAP) can be more appropriately used when the *APC* gene is mutated, as in the classical FAP, whereas *MUTYH*-associated polyposis (MAP) is preferred when *MUTYH* mutations are found. However, many patients with AAP remains "genetic orphans", because at present, no constitutional mutation can be demonstrated^[12,13]. Moreover, mutations in other genes can cause rare forms of attenuated polyposis^[14].

As mentioned above, there is still controversy also on the morphology of polyps that should be included in the definition of attenuated polyposis. In fact, according to some authors, hyperplastic or serrated polyposis should be included in this category^[15,16], considering the risk of developing colorectal cancer in these forms of intestinal polyposis^[17]. Other polyposis have peculiar morphologic characteristics that allow to classify them as Hamartomatous polyposis syndromes (Peutz-Jeghers syndrome, Juvenile polyposis, and Cowden syndrome).

Thus, the picture is far to be completely elucidated, and, despite attempts to refine diagnostic accuracy, AFAP still remains poorly understood and defined. We think that, before proceeding toward the genetic diagnosis, it is mandatory to try to reach a useful definition of the syndrome that we prefer to refer to as AAP. Probably one possible definition is to consider as AAP any patient with synchronous adenomas of the large bowel ranging between 10 and 99, not considering age of onset, other clinical features, or formal and molecular genetics. Of course this definition is totally clinical, and, as all definitions, it reflects only part of the truth. For example, near the upper and lower limits of 10 and 99 adenomas it is impossible to sharply cut off sporadic multiple adenomas for the lower limit, and classical FAP for the upper. Moreover, we do not know whether the development of further metachronous adenomas during surveillance of patients may change the definition and the management of the syndrome. Another controversial issue is the presence in the family of other patients with adenomas or cancer^[10]. However this definition has the advantage of simplicity, and it allows to have a solid ground on which rely for the genetic and clinical management of affected patients and family members. Another issue is the fraction of adenomas on the total number of polyps necessary to define an adenomatous polyposis. We think that at least 50% histologically confirmed adenomas are necessary for the definition of AAP^[9].

Since the definition is unclear and there is no real consensus, incidence and frequency of AAP are difficult to establish. Frequency may be estimated to be less than 15% of all adenomatous polyposis, but a systematic search for AAP has never been carried out. As mentioned above, the age of onset of AAP is delayed as compared with FAP^[5,9], adenomas seem more prevalent in the proximal colon^[18,19], to spare the rectum^[20], and they tend to be flat^[21,22], and sometimes also hyperplastic polyps and flat serrated adenomas are present^[23]. The risk of developing cancer is not 100% as in classical FAP. Extracolonic manifestations [duodenal adenomas, periampullary carcinoma, desmoid tumors, osteomas, epidermoid cysts, congenital hypertrophy of the retinal pigmented epithelium (CHRPE), supernumerary teeth, thyroid carcinoma, and hepatoblastoma] seem less frequent than in FAP, though studies are very few on this topic^[23,24].

As mentioned, genetic testing should be offered to patients with AAP. *APC* and *MUTYH* are the two genes most frequently involved in the pathogenesis of AAP. However, constitutional mutations of other known and unknown genes contribute to the AAP phenotype.

APC is a tumor-suppressor gene, located on the long arm of chromosome 5^[25]. In classical FAP a mutated allele is inherited, the other allele is damaged or lost by a somatic event, and this allows the growth of adenomas. Then, other mutational events in other genes are required to push ahead the malignant transformation. Some correlations between the site of the mutations within the open reading frame of the gene and the clinical manifestations of the disease have been reported so far (the so-called genotype-phenotype correlations)^[26]. As far as AAP is concerned, the overall frequency of *APC* mutations is difficult to establish, however it can be estimated around 10%-20% of patients with less than 100 adenomas^[9]. In these cases, AAP (namely AFAP) is inherited as an autosomal dominant disease, as it happens for classical FAP. In AAP, we know that *APC* mutations are found mostly near the 5' and 3' ends of the gene, and sometimes on exon 9^[7,26], but other regions of the gene can be mutated.

MUTYH is a base excision repair gene whose protein repairs oxidative damage to DNA^[4]. Biallelic mutations of that gene cause CG-AT transversions in several other genes, including *APC* and *RAS*. The two most frequent mutations found in patients with AAP are Y179C and G396D, both missense^[27]. Thus, *MUTYH*-associated polyposis (MAP) has a recessive pattern of inheritance, and it is particularly frequent in patients with less than 100 adenomas^[28,29], though *MUTYH* mutations may be found also in a small fraction of patients with classical FAP and no *APC* mutation^[28]. It can be estimated that *MUTYH* is mutated in 20%-40% of patients with AAP^[12,29]. Mean age at diagnosis seems delayed, when compared with patients with *APC* mutations^[30]. Mutations in one allele

only of the *MUTYH* gene seem not to confer a higher risk of developing intestinal adenomatous polyposis.

Recently, other genes that may be constitutionally mutated in intestinal polyposis syndromes, were found associated with the AAP phenotype. These genes, involved in DNA synthesis are polymerase D1 (*POLD1*) and polymerase E gene (*POLE*). Mutations in one of these genes cause the rare Polymerase Proofreading-Associated Polyposis (PPAP)^[14], which is inherited as an autosomal dominant trait. Mutations in these genes have been reported so far also for Lynch syndrome, and probably cause an excess also of brain tumors^[31].

Constitutional mutations in other genes may explain a certain fraction of AAP: *NTHL1*^[32], *MSH3*^[33], *FOCAD*^[34], *POLD3* or other polymerase genes^[35]. In the near future, other genes will be discovered in the germline of patients with AAP.

No established guidelines exist for the management of AAP. When a mutation is found in *APC* or *MUTYH* (biallelic), a colonoscopy should be carried out, beginning at puberty, along with esophago-gastroduodenoscopy, and repeated over time every 2-3 years, and then regularly. However, since the genetic test is often negative for constitutional mutation, management is empirical and based on clinical findings in most cases. The choice of following a patient endoscopically or with a surgical approach is a matter of debate. The more convenient program is to continue an endoscopic follow-up when all polyps can be removed during colonoscopy, and to counsel surgery when the number of polyps is high or with multiple diminutive polyps, or in case of low compliance, or when a severe dysplasia or cancer is found at histological examination in one or more polyps^[8,36]. When surgery is necessary, and the rectum is spared by polyps, a subtotal colectomy with ileo-rectal anastomosis is the treatment of choice^[37]. Sometimes, when a severe phenotype (profuse polyposis) is present, due to mutations in particular zones of the genes, the surgical resection should be enlarged^[38,39]. At variance with FAP, no valuable information is available for chemoprevention with non-steroidal anti-inflammatory or other drugs in AAP, though the smaller number of polyps might be an advantage. Surveillance for upper gastrointestinal lesions (gastric polyps and duodenal/jejunal adenomas) with gastroduodenoscopy may be recommended at lapses of time guided by the Spigelman' stage of duodenal polyposis, as in FAP, but no data are available at the moment^[8].

CONCLUSION

AAP is a poorly defined syndrome which deserves further research. It may be defined as the presence of 10-99 synchronous adenomas in the large bowel, when at least 50% of the polyps removed are adenomatous (otherwise other polyposis syndromes should be suspected). This definition has the advantage of simplicity, but it may include sporadic multiple

adenomas of the large bowel at an extreme, or FAP cases at the upper limit. AAP shows a milder phenotype than FAP, with an older age of onset of adenomas and cancer, and less frequent extracolonic manifestations. AAP may be diagnosed as a single case in a family or, less frequently, it may be present in other family members. In less than 50% of cases, it may be caused by *APC* or *MUTYH* mutations, referred to as *APC*-associated polyposis (AFAP), or *MUTYH*-associated polyposis (MAP), respectively. Surveillance should rely on colonoscopy at regular intervals, with removal of adenomas and careful histological examination. If removal of all polyps is not possible or advanced lesions are observed, the surgical treatment is mandatory. With no doubt, we need further insights into the undefined and poorly understood issue of AAP.

ACKNOWLEDGMENTS

The authors recognize the continuous support of the Associazione per lo Ricerca Sui Tumori Intestinali (ARTI).

REFERENCES

- Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. *Orphanet J Rare Dis* 2009; **4**: 22 [PMID: 19822006 DOI: 10.1186/1750-1172-4-22]
- Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identification of FAP locus genes from chromosome 5q21. *Science* 1991; **253**: 661-665 [PMID: 1651562 DOI: 10.1126/science.1651562.]
- Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M. Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991; **66**: 589-600 [PMID: 1651174 DOI: 10.1016/0092-8674(81)90021-0]
- Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP. Inherited variants of MYH associated with somatic G:C->T mutations in colorectal tumors. *Nat Genet* 2002; **30**: 227-232 [PMID: 11818965 DOI: 10.1038/ng828]
- Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. *Dis Colon Rectum* 2002; **45**: 127-134; discussion 134-136 [PMID: 11786778 DOI: 10.1007/s10350-004-6127-y]
- Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. *Fam Cancer* 2003; **2**: 43-55 [PMID: 14574166]
- Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, Kuwada SK, Neklason DW, Disario JA, Lyon E, Hughes JP, Chey WY, White RL. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. *Gastroenterology* 2004; **127**: 444-451 [PMID: 15300576 DOI: 10.1053/j.gastro.2004.05.003]
- Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol* 2015; **110**: 223-262; quiz 263 [PMID: 25645574 DOI: 10.1038/ajg.2014.435]
- de Leon MP, Pedroni M, Roncucci L, Domati F, Rossi G, Magnani G, Pezzi A, Fante R, Bonetti LR. Attenuated polyposis of the large bowel: a morphologic and molecular approach. *Fam Cancer* 2017; **16**: 211-220 [PMID: 27783336 DOI: 10.1007/s10689-016-9938-9]
- Nielsen M, Hes FJ, Nagengast FM, Weiss MM, Mathus-Vliegen EM, Morreau H, Breuning MH, Wijnen JT, Tops CM, Vasen HF. Germline mutations in *APC* and *MUTYH* are responsible for the majority of families with attenuated familial adenomatous polyposis. *Clin Genet* 2007; **71**: 427-433 [PMID: 17489848 DOI: 10.1111/j.1399-0004.2007.00766.x]
- Filipe B, Baltazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I, Mão de Ferro S, Claro I, Rodrigues P, Fidalgo P, Chaves P, Cravo M, Nobre Leitão C. *APC* or *MUTYH* mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. *Clin Genet* 2009; **76**: 242-255 [PMID: 19793053 DOI: 10.1111/j.1399-0004.2009.01241.x]
- Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GM, Halling KC, French AJ, Johnson RA, Burgart LJ, Rabe K, Lindor NM, Thibodeau SN. *MYH* mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. *Gastroenterology* 2004; **127**: 9-16 [PMID: 15236166 DOI: 10.1053/j.gastro.2004.03.070]
- de Leon MP, Urso ED, Pucciarelli S, Agostini M, Nitti D, Roncucci L, Benatti P, Pedroni M, Kaleci S, Balsamo A, Laudi C, Di Gregorio C, Viel A, Rossi G, Venesio T. Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. *Tech Coloproctol* 2013; **17**: 79-87 [PMID: 22976915 DOI: 10.1007/s10151-012-0887-5]
- Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJ, McVean G, Houlston RS, Tomlinson I. Germline mutations affecting the proofreading domains of *POLE* and *POLD1* predispose to colorectal adenomas and carcinomas. *Nat Genet* 2013; **45**: 136-144 [PMID: 23263490 DOI: 10.1038/ng.2503]
- Gill P, Wang LM, Bailey A, East JE, Leedham S, Chetty R. Reporting trends of right-sided hyperplastic and sessile serrated polyps in a large teaching hospital over a 4-year period (2009-2012). *J Clin Pathol* 2013; **66**: 655-658 [PMID: 23576460 DOI: 10.1136/jclinpath-2013-201608]
- Hazewinkel Y, Tytgat KM, van Eeden S, Bastiaansen B, Tanis PJ, Boparai KS, Fockens P, Dekker E. Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. *Gastroenterology* 2014; **147**: 88-95 [PMID: 24657624 DOI: 10.1053/j.gastro.2014.03.015]
- Boparai KS, van den Broek FJ, van Eeden S, Fockens P, Dekker E. Increased polyp detection using narrow band imaging compared with high resolution endoscopy in patients with hyperplastic polyposis syndrome. *Endoscopy* 2011; **43**: 676-682 [PMID: 21811939 DOI: 10.1055/s-0030-1256447]
- Lynch HT, Smyrk TC. Classification of familial adenomatous polyposis: a diagnostic nightmare. *Am J Hum Genet* 1998; **62**: 1288-1289 [PMID: 9585618 DOI: 10.1086/301890]
- O'Shea AL, Järvinen H, Peltomäki P. Genetic and clinical characterisation of familial adenomatous polyposis: a population based study. *Gut* 2002; **50**: 845-850 [PMID: 12010888 DOI: 10.1136/gut.50.6.845]
- Rozen P, Samuel Z, Shomrat R, Legum C. Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an *APC* mutation in exon 9. *Gut* 1999; **45**: 829-833 [PMID: 10562580 DOI: 10.1136/gut.45.6.829]
- Matsubara N, Iozaki H, Tanaka N. The farthest 3' distal end *APC* mutation identified in attenuated adenomatous polyposis coli with extracolonic manifestations. *Dis Colon Rectum* 2000; **43**: 720-721 [PMID: 10826438 DOI: 10.1007/BF02235596]
- O'Shea AM, Cleary SP, Croitoru MA, Kim H, Berk T, Monga N, Riddell RH, Pollett A, Gallinger S. Pathological features of colorectal carcinomas in *MYH*-associated polyposis. *Histopathology* 2008; **53**: 184-194 [PMID: 18564191 DOI: 10.1007/s10689-016-9938-9]

- 10.1111/j.1365-2559.2008.03071.x]
- 23 **Boparai KS**, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM, Keller JJ, van Noesel CJ. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology* 2008; **135**: 2014-2018 [PMID: 19013464 DOI: 10.1053/j.gastro.2008.09.020]
 - 24 **Su LK**, Barnes CJ, Yao W, Qi Y, Lynch PM, Steinbach G. Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. *Am J Hum Genet* 2000; **67**: 582-590 [PMID: 10924409 DOI: 10.1086/303058]
 - 25 **Bodmer WF**, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, Lucibello FC, Murday VA, Rider SH, Scambler P. Localization of the gene for familial adenomatous polyposis on chromosome 5. *Nature* 1987; **328**: 614-616 [PMID: 3039373 DOI: 10.1038/328614a0]
 - 26 **Nieuwenhuis MH**, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. *Crit Rev Oncol Hematol* 2007; **61**: 153-161 [PMID: 17064931 DOI: 10.1016/j.critrevonc.2006.07.004]
 - 27 **Sieber OM**, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson SV, Thomas HJ, Tomlinson IP. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med* 2003; **348**: 791-799 [PMID: 12606733 DOI: 10.1056/NEJMoa025283]
 - 28 **Sampson JR**, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, Frayling I, Jordan S, Maher ER, Mak T, Maynard J, Pigatto F, Shaw J, Cheadle JP. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. *Lancet* 2003; **362**: 39-41 [PMID: 12853198 DOI: 10.1016/S0140-6736(03)13805-6]
 - 29 **Venesio T**, Molatore S, Cattaneo F, Arrigoni A, Risio M, Ranzani GN. High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. *Gastroenterology* 2004; **126**: 1681-1685 [PMID: 15188161 DOI: 10.1053/j.gastro.2004.02.022]
 - 30 **Marabelli M**, Molinaro V, Khouzam RA, Berrino E, Panero M, Balsamo A, Venesio T, Ranzani GN. Colorectal Adenomatous Polyposis: Heterogeneity of Susceptibility Gene Mutations and Phenotypes in a Cohort of Italian Patients. *Genet Test Mol Biomarkers* 2016; **20**: 777-785 [PMID: 27705013 DOI: 10.1089/gtmb.2016.0198]
 - 31 **Bellido F**, Pineda M, Aiza G, Valdés-Mas R, Navarro M, Puente DA, Pons T, González S, Iglesias S, Darder E, Piñol V, Soto JL, Valencia A, Blanco I, Urioste M, Brunet J, Lázaro C, Capellá G, Puente XS, Valle L. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. *Genet Med* 2016; **18**: 325-332 [PMID: 26133394 DOI: 10.1038/gim.2015.75]
 - 32 **Weren RD**, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, van Zelst-Stams WA, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA, Kamping EJ, Nagtegaal ID, Tops BB, Nagengast FM, Geurts van Kessel A, van Krieken JH, Kuiper RP, Hoogerbrugge N. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. *Nat Genet* 2015; **47**: 668-671 [PMID: 25938944 DOI: 10.1038/ng.3287]
 - 33 **Adam R**, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, Kirfel J, Tafazzoli A, Horpaopan S, Uhlhaas S, Stienen D, Friedrichs N, Altmüller J, Laner A, Holzapfel S, Peters S, Kayser K, Thiele H, Holinski-Feder E, Marra G, Kristiansen G, Nöthen MM, Büttner R, Möslein G, Betz RC, Brieger A, Lifton RP, Aretz S. Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. *Am J Hum Genet* 2016; **99**: 337-351 [PMID: 27476653 DOI: 10.1016/j.ajhg.2016.06.015]
 - 34 **Weren RD**, Venkatachalam R, Cazier JB, Farin HF, Kets CM, de Voer RM, Vreede L, Verwiel ET, van Asseldonk M, Kamping EJ, Kiemeny LA, Neveling K, Aben KK, Carvajal-Carmona L, Nagtegaal ID, Schackert HK, Clevers H, van de Wetering M, Tomlinson IP, Ligtenberg MJ, Hoogerbrugge N, Geurts van Kessel A, Kuiper RP. Germline deletions in the tumour suppressor gene FOCAD are associated with polyposis and colorectal cancer development. *J Pathol* 2015; **236**: 155-164 [PMID: 25712196 DOI: 10.1002/path.4520]
 - 35 **Spier I**, Holzapfel S, Altmüller J, Zhao B, Horpaopan S, Vogt S, Chen S, Morak M, Raeder S, Kayser K, Stienen D, Adam R, Nürnberg P, Plotz G, Holinski-Feder E, Lifton RP, Thiele H, Hoffmann P, Steinke V, Aretz S. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer* 2015; **137**: 320-331 [PMID: 25529843 DOI: 10.1002/ijc.29396]
 - 36 **Fornasarig M**, Minisini AM, Viel A, Quaia M, Canzonieri V, Veronesi A. Twelve years of endoscopic surveillance in a family carrying biallelic Y165C MYH defect: report of a case. *Dis Colon Rectum* 2006; **49**: 272-275 [PMID: 16416081 DOI: 10.1007/s10350-005-0257-8]
 - 37 **Bülow C**, Vasen H, Järvinen H, Björk J, Bisgaard ML, Bülow S. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. *Gastroenterology* 2000; **119**: 1454-1460 [PMID: 11113066 DOI: 10.1053/gast.2000.20180]
 - 38 **Rozen P**, Macrae F. Familial adenomatous polyposis: The practical applications of clinical and molecular screening. *Fam Cancer* 2006; **5**: 227-235 [PMID: 16998668 DOI: 10.1007/s10689-005-5674-2]
 - 39 **Nielsen M**, Joerink-van de Beld MC, Jones N, Vogt S, Tops CM, Vasen HF, Sampson JR, Aretz S, Hes FJ. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. *Gastroenterology* 2009; **136**: 471-476 [PMID: 19032956 DOI: 10.1053/j.gastro.2008.10.056]

P- Reviewer: Garcia-Olmo D, Topaloglu S **S- Editor:** Qi Y
L- Editor: A **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgooffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045